- ￥2200
- Biorigin
- BN40853R
- 2025年08月02日
- IHC-P,FCM，
- Human,Mouse,Rat,Dog,Rabbit,
18 年金牌会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 适应物种：
Human,Mouse,Rat,Dog,Rabbit,
- 应用范围：
IHC-P,FCM，
- 抗体英文名：
Phospho-Bcl-2 (Ser70)
- 规格：
100ul
| 英文名称 | Phospho-Bcl-2 (Ser70) |
| 中文名称 | 磷酸化Bcl-2抗体 |
| 别 名 | Bcl2 (phospho S70); p-Bcl2 (phospho S70); Apoptosis regulator Bcl 2; Apoptosis regulator Bcl2; AW986256; B cell CLL/lymphoma 2; B cell leukemia/lymphoma 2; B cell lymphoma 2; Bcl 2; Bcl-2; Bcl2; BCL2 protein; C430015F12Rik; D630044D05Rik; D830018M01Rik; Leukemia/lymphoma, B-cell, 2; Oncogene B-cell leukemia 2; BCL2_HUMAN |
| 产品类型 | 磷酸化抗体 |
| 研究领域 | 肿瘤 细胞生物 神经生物学 信号转导 细胞凋亡 线粒体 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, (predicted: Mouse, Rat, Dog, Rabbit, ) |
| 产品应用 | ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1ug/test IF=1:100-500 （石蜡切片需做抗原修复） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 26kDa |
| 细胞定位 | 细胞核 细胞浆 细胞膜 线粒体 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated Synthesised phosphopeptide derived from rat Bcl-2 around the phosphorylation site of Ser70:RT(p-S)PL |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| PubMed | PubMed |
| 产品介绍 | BCL2 is an integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Two transcript variants (alpha and beta) produced by alternate splicing, differ in their C-terminal ends. BCL2 suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. It regulates cell death by controlling the mitochondrial membrane permeability. It appears to function in a feedback loop system with caspases. BCL2 inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF1). It can form homodimers, and heterodimers with BAX, BAD, BAK and BclX(L). Heterodimerization with BAX requires intact BH1 and BH2 domains, and is necessary for anti-apoptotic activity. Also interacts with APAF1, RAF1, TP53BP2, BBC3, BCL2L1 and BNIPL. Function: Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). Subunit: Forms homodimers, and heterodimers with BAX, BAD, BAK and Bcl-X(L). Heterodimerization with BAX requires intact BH1 and BH2 motifs, and is necessary for anti-apoptotic activity. Interacts with EI24. Also interacts with APAF1, BBC3, BCL2L1, BNIPL, MRPL41 and TP53BP2. Binding to FKBP8 seems to target BCL2 to the mitochondria and probably interferes with the binding of BCL2 to its targets. Interacts with BAG1 in an ATP-dependent manner. Interacts with RAF1 (the 'Ser-338' and 'Ser-339' phosphorylated form). Interacts (via the BH4 domain) with EGLN3; the interaction prevents the formation of the BAX-BCL2 complex and inhibits the anti-apoptotic activity of BCL2. Interacts with G0S2; this interaction also prevents the formation of the anti-apoptotic BAX-BCL2 complex. Subcellular Location: Mitochondrion outer membrane; Single-pass membrane protein. Nucleus membrane; Single-pass membrane protein. Endoplasmic reticulum membrane; Single-pass membrane protein. Tissue Specificity: Expressed in a variety of tissues. Post-translational modifications: Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation on Ser-70 by PKC is required for the anti-apoptosis activity and occurs during the G2/M phase of the cell cycle. In the absence of growth factors, BCL2 appears to be phosphorylated by other protein kinases such as ERKs and stress-activated kinases. Phosphorylated by MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulates starvation-induced autophagy. Dephosphorylated by protein phosphatase 2A (PP2A). Proteolytically cleaved by caspases during apoptosis. The cleaved protein, lacking the BH4 motif, has pro-apoptotic activity, causes the release of cytochrome c into the cytosol promoting further caspase activity. Monoubiquitinated by PARK2, leading to increase its stability. DISEASE: Note=A chromosomal aberration involving BCL2 has been found in chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions. Similarity: Belongs to the Bcl-2 family. SWISS: P49950 Gene ID: 596 Database links: Entrez Gene: 596 Human Entrez Gene: 12043 Mouse Omim: 151430 Human SwissProt: P10415 Human SwissProt: P10417 Mouse Unigene: 150749 Human Unigene: 257460 Mouse Unigene: 9996 Rat
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
青鸟使者 小弟刚接触细胞信号转导，做VEGFR-2，有个基础的菜鸟问题，VEGFR-2有6个自磷酸化位点，我做的是抑制其磷酸化的小分子抑制剂，观察其对VEGFR-2磷酸化的抑制作用，那western-blot时选哪个磷酸化位点的抗体检测好呢？还是都一样？先谢谢高手相助！ xb0810 应该先看看文献，一般下游不同的分支的激活可能与不同的位点磷酸化有关。 shutaozheng_824 还是查
prince1101 非磷酸化抗体是识别总得蛋白的，比如AKT。 P-AKT和AKT其实只差一些磷酸基，分子量稍大点，以前听别人讲P-AKT和AKT之间有shift，有时候WB是可以做出来的。 用的是梯度胶？分子量在68KD左右。应该怎么样来配胶呢？梯度胶的浓度？ 谢谢！ prince1101 希望高手能赐教！ ourlab 某些 AKT抗体，如cell
【求助】如果要证明Bcl-2和RARP活性，应该做什么实验？
；如果您使用的是parp抑制剂，那么bcl-2依然可能会降低，caspase-3也可能会激活，但parp的活化应该不明显或相对不明显，就可初步得到证实。 eeflying 我需要的是直接效应实验， 就像EGFR抑制剂可以用磷酸化WB验证一样的直接实验。 doctormy eeflying wrote: 我需要的是直接效应实验， 就像EGFR抑制剂可以用磷酸化WB验证一样的直接
技术资料暂无技术资料 索取技术资料
磷酸化Bcl-2抗体
￥2200
